Search

Your search keyword '"E. Andreakos"' showing total 122 results

Search Constraints

Start Over You searched for: Author "E. Andreakos" Remove constraint Author: "E. Andreakos"
122 results on '"E. Andreakos"'

Search Results

1. Nasal epithelium: new insights and differences of the cytokine profile between normal subjects and subjects with allergic rhinitis

2. Poster Session 3: Friday 9 December 2011, 08:30-12:30 * Location: Poster Area

3. Common and Uncommon Features of Rheumatoid Arthritis and Chronic Obstructive Pulmonary Disease: Clues to a Future Therapy

4. Activin-A Overexpression in the Murine Lung Causes Pathology That Simulates Acute Respiratory Distress Syndrome

5. Targeting intracellular mediators of pattern-recognition receptor signalling to adjuvant vaccination.

6. Autoantibodies against type I IFNs in patients with critical influenza pneumonia

7. Sialylated IgG induces the transcription factor REST in alveolar macrophages to protect against lung inflammation and severe influenza disease.

8. scRNA-Explorer: An End-user Online Tool for Single Cell RNA-seq Data Analysis Featuring Gene Correlation and Data Filtering.

9. BioTextQuest v2.0: An evolved tool for biomedical literature mining and concept discovery.

10. Notch signaling in adipose tissue macrophages prevents diet-induced inflammation and metabolic dysregulation.

11. Type III interferons in innate and adaptive immunity in the respiratory tract.

12. Type I and type III interferons: From basic biology and genetics to clinical development for COVID-19 and beyond.

13. Current Insights into Tissue Injury of Giant Cell Arteritis: From Acute Inflammatory Responses towards Inappropriate Tissue Remodeling.

14. Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children.

15. Comprehensive Analysis of 1-Year-Old Female Apolipoprotein E-Deficient Mice Reveals Advanced Atherosclerosis with Vulnerable Plaque Characteristics.

16. Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs.

18. Respiratory eukaryotic virome expansion and bacteriophage deficiency characterize childhood asthma.

19. Respiratory virome profiles reflect antiviral immune responses.

20. Autoantibodies are highly prevalent in non-SARS-CoV-2 respiratory infections and critical illness.

21. Transcriptomic-based clustering of human atherosclerotic plaques identifies subgroups with different underlying biology and clinical presentation.

22. Development of an in vitro homeostasis model between airway epithelial cells, bacteria and bacteriophages: a time-lapsed observation of cell viability and inflammatory response.

23. Autoantibodies against type I IFNs in patients with critical influenza pneumonia.

25. Decoding the Human Genetic and Immunological Basis of COVID-19 mRNA Vaccine-Induced Myocarditis.

26. Prediction and Ranking of Biomarkers Using multiple UniReD.

27. Prevalence of the BRAF V600E mutation in Greek adults with Langerhans cell histiocytosis.

28. Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries.

29. TFEB signaling attenuates NLRP3-driven inflammatory responses in severe asthma.

30. Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis.

31. Severity of neonatal influenza infection is driven by type I interferon and oxidative stress.

32. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.

33. Comparative assessment of allergic reactions to COVID-19 vaccines in Europe and the United States.

34. CD103 integrin identifies a high IL-10-producing FoxP3 + regulatory T-cell population suppressing allergic airway inflammation.

35. Corrigendum: Interactions of Bacteriophages and Bacteria at the Airway Mucosa: New Insights Into the Pathophysiology of Asthma.

37. Mesenchymal stromal cell delivery as a potential therapeutic strategy against COVID-19: Promising evidence from in vitro results.

38. Protocol for influenza A virus infection of mice and viral load determination.

40. A global effort to dissect the human genetic basis of resistance to SARS-CoV-2 infection.

41. Autoantibodies targeting cytokines and connective tissue disease autoantigens are common in acute non-SARS-CoV-2 infections.

42. C-type lectin receptor CLEC4A2 promotes tissue adaptation of macrophages and protects against atherosclerosis.

43. A Multimodal Approach for the Risk Prediction of Intensive Care and Mortality in Patients with COVID-19.

44. Differential maturation trajectories of innate antiviral immunity in health and atopy.

45. Genetic regulation of OAS1 nonsense-mediated decay underlies association with risk of severe COVID-19.

46. Impaired innate antiviral defenses in COVID-19: Causes, consequences and therapeutic opportunities.

47. COVID-19 enters the expanding network of apolipoprotein E4-related pathologies.

49. Interactions of Bacteriophages and Bacteria at the Airway Mucosa: New Insights Into the Pathophysiology of Asthma.

50. Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison.

Catalog

Books, media, physical & digital resources